Resources from the same session
515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Presenter: Haeseong Park
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Presenter: Natalie Cook
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
518MO - Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
Presenter: Manish Sharma
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
519MO - Concordance analysis of treatment recommendations between central consensus and multidisciplinary tumor boards
Presenter: Hidenori Kage
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum
Presenter: Julia Lai-Kwon
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Discussion 515MO and 516MO
Presenter: Aung Naing
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
Discussion 517MO and 518MO
Presenter: Richard Schlenk
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast